Shares of Moderna finished March 11 down by 93% from their peak in 2021. In addition to its COVID-19 vaccine, Moderna markets ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, ...

Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to protect adults aged 60 years and older against lower ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the ...

Feb 28 (Reuters) - Britain's health regulator said on Friday it has approved Moderna's (MRNA.O), opens ... Sign up here. RSV is a common virus that spreads very easily and causes infections ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting ...